| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
Glaucoma is a disease that damages the eye's optic nerve and retinal ganglion cells (RGC), resulting in vision loss and blindness. The purpose of the present study was to determine whether the inhibition of mitochondrial μ-calpain protects the RGC in one of the animal models of glaucoma.
I used a well-established rat model of experimental acute glaucoma, ischemia/reperfusion injury. The specific peptide inhibitor of mitochondrial μ-calpain, Tat-μCL, was used for the topical eye-drop application. I applied eye-drops containing 1 mM Tat-μCL to rats three times a day for 5 days after I/R. RGC death was determined by TUNEL assay. The change of retinal function was examined by electroretinogram (ERG).
Eye-drop application of Tat-μCL significantly prevented the RGC death. The Tat-μCL significantly inhibited the decrease of RGC. In addition, both a- and b-wave in ERG were attenuated after I/R, but the eye-drop application of Tat-μCL significantly recovered the attenuation.
|
